Thomas F. Woiwode, Ph.D.
Thomas F. Woiwode, Ph.D. became a member of Adverum’s board of directors upon completion of the merger of Avalanche Biotechnologies and Annapurna Therapeutics in 2016. Dr. Woiwode has been with Versant Ventures since 2002, serving as a venture partner since 2008 and a managing director since 2014. He has served in a number of operating roles over this time, most recently as the chief operating officer of Okairos, which was sold to GlaxoSmithKline plc. Previously, Dr. Woiwode co-founded EuroVentures, a wholly-owned biotech incubator within Versant Ventures, where he served as the founding chief business officer for three biotechnology companies created within Versant, including Flexion (public), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb). Prior to his role as a venture partner, he was a principal at Versant Ventures and served on the boards of Antipodean Pharmaceuticals, CymaBay Therapeutics, Inc. (previously known as Metabolex Inc.) and Saegis Pharmaceuticals. Previously, he was a research scientist at XenoPort Inc. He earned a Ph.D. in Organic Chemistry as an NSF Fellow at Stanford University. He graduated summa cum laude with a B.A. in English and received the Departmental Citation for a B.S. in Chemistry from University of California, Berkeley.